Drug Profile
Recombinant MFG-E8 - TheraSource
Alternative Names: Recombinant human MFG-E8; Recombinant lactadherin; Recombinant MFG-E8; rhMFG-E8Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator TheraSource
- Class Anti-inflammatories; Antihaemorrhagics; Proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute kidney injury; Haemorrhagic shock; Inflammatory bowel diseases
Highest Development Phases
- No development reported Acute kidney injury; Haemorrhagic shock; Inflammatory bowel diseases
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Haemorrhagic shock(Adjuvant therapy) in USA (IV)
- 28 Apr 2019 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (SC, Injection)
- 28 Aug 2018 No recent reports of development identified for preclinical development in Acute kidney injury in USA (IV)